Article Text

Download PDFPDF
Non-recurrent SEPT9 duplications cause hereditary neuralgic amyotrophy
  1. A M B Collie1,
  2. M L Landsverk1,13,
  3. E Ruzzo1,
  4. H C Mefford1,2,3,
  5. K Buysse4,
  6. J R Adkins1,
  7. D M Knutzen1,
  8. K Barnett1,
  9. R H Brown Jr5,
  10. G J Parry6,
  11. S W Yum7,
  12. D A Simpson8,
  13. R K Olney9,
  14. P F Chinnery10,
  15. E E Eichler2,11,
  16. P F Chance1,4,12,
  17. M C Hannibal1,4
  1. 1Department of Pediatrics, University of Washington School of Medicine, Seattle, Washington, USA
  2. 2Department of Genome Sciences, University of Washington School of Medicine, Seattle, Washington, USA
  3. 3Seattle Children's Hospital and Regional Medical Center, Seattle, Washington, USA
  4. 4Center for Medical Genetics, Ghent University Hospital, Ghent, Belgium
  5. 5Department of Neurology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
  6. 6Department of Neurology, University of Minnesota, Minneapolis, Minnesota, USA
  7. 7Division of Neurology, The Children's Hospital of Philadelphia and University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA
  8. 8Michigan Institute for Neurological Disorders, Farmington Hills, Michigan, USA
  9. 9Department of Neurology, University of California San Francisco, San Francisco, California, USA
  10. 10Mitochondrial Research Group, Institute for Ageing and Health, Newcastle University, Newcastle Upon Tyne, UK
  11. 11Howard Hughes Medical Institute, Seattle, Washington, USA
  12. 12Department of Neurology, University of Washington School of Medicine, Seattle, Washington, USA
  13. 13Department of Molecular & Human Genetics, Baylor Collegeof Medicine, Houston, Texas, USA
  1. Correspondence to Megan L Landsverk, Department of Molecular & Human Genetics, Baylor College of Medicine, Houston, TX 77030, USA; mllandsverk{at}


Background Genomic copy number variants have been shown to be responsible for multiple genetic diseases. Recently, a duplication in septin 9 (SEPT9) was shown to be causal for hereditary neuralgic amyotrophy (HNA), an episodic peripheral neuropathy with autosomal dominant inheritance. This duplication was identified in 12 pedigrees that all shared a common founder haplotype.

Methods and results Based on array comparative genomic hybridisation, we identified six additional heterogeneous tandem SEPT9 duplications in patients with HNA that did not possess the founder haplotype. Five of these novel duplications are intragenic and result in larger transcript and protein products, as demonstrated through reverse transcription-PCR and western blotting. One duplication spans the entire SEPT9 gene and does not generate aberrant transcripts and proteins. The breakpoints of all the duplications are unique and contain regions of microhomology ranging from 2 to 9 bp in size. The duplicated regions contain a conserved 645 bp exon within SEPT9 in which HNA-linked missense mutations have been previously identified, suggesting that the region encoded by this exon is important to the pathogenesis of HNA.

Conclusions Together with the previously identified founder duplication, a total of seven heterogeneous SEPT9 duplications have been identified in this study as a causative factor of HNA. These duplications account for one third of the patients in our cohort, suggesting that duplications of various sizes within the SEPT9 gene are a common cause of HNA.

  • Clinical genetics
  • molecular genetics
  • peripheral nerve disease

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Funding This work was supported by a fellowship from the Research Foundation — Flanders (FWO) (to KB); the National Institutes of Heath, grant number NS38181 (to PF Chance and MCH); The Neuropathy Association, New York, New York (to PFC); and the Allan and Phyllis Treuer Endowed Chair for Genetics and Development (to PF Chance). PF Chinnery is a Wellcome Trust Senior Fellow in Clinical Science who also receives funding from the Medical Research Council (UK), the UK Parkinson's Disease Society, and the UK National Institute for Health Research Biomedical Research Centre for Ageing and Age-Related Disease award to the Newcastle upon Tyne Foundation Hospitals NHS Trust.

  • Competing interests None.

  • Ethics approval This study was conducted with the approval of the University of Washington.

  • Provenance and peer review Not commissioned; externally peer reviewed.